Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14160472 | 1.00 | KIF11 (0.37) | KIF11ALOX5SMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL18951922 | 0.98 | KIF11 (0.36) | KIF11ALOX5SMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL929644 | 0.98 | KIF11 (0.36) | KIF11ALOX5SMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL929641 | 0.98 | KIF11 (0.36) | KIF11ALOX5SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11861945 | 0.84 | SMN1; SMN2 (0.36) | ALOX5SMN1; SMN2ALDH1A1 | |
| SCHEMBL20077224 | 0.84 | KIF11 (0.38) | KIF11SMN1; SMN2ARG1ARG2 | |
| SCHEMBL4412611 | 0.82 | ALOX5 (0.34) | ALOX5SMN1; SMN2ARG1ARG2 | |
| SCHEMBL557341 | 0.82 | MAPT (0.35) | ALOX5SMN1; SMN2ARG1ARG2ALDH1A1 | |
| SCHEMBL23129041 | 0.81 | KIF11 (0.40) | KIF11SMN1; SMN2ARG1ARG2 | |
| SCHEMBL1709969 | 0.81 | KIF11 (0.40) | KIF11SMN1; SMN2ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180362456-A1 | NEW COMPOUNDS WITH ANTIOXIDANT AND ANTIAGING ACTIVITY | EMS S/A (BR) | 2018-12-20 | — | — | US | disclosed |
| WO-2017096450-A1 | NEW COMPOUNDS WITH ANTIOXIDANT AND ANTIAGING ACTIVITY | EMS S/A (BR) | 2017-06-15 | — | — | WO | disclosed |
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| US-8710178-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | LINCOLN UNIVERSITY (NZ) | 2014-04-29 | — | — | US | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
| WO-2008048121-A2 | MACROCYCLIC CYSTEINE PROTEASE INHIBITORS AND COMPOSITIONS THEREOF | LINCOLN UNIVERSITY (NZ) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362456-A1 | NEW COMPOUNDS WITH ANTIOXIDANT AND ANTIAGING ACTIVITY | GPX1, CAT, GPX4 | KIF11 4507/4885ALOX5 193/4885SMN1; SMN2 2003/4885 |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | KIF11 3435/4885ALOX5 2562/4885SMN1; SMN2 2726/4885 |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | KIF11 3435/4885ALOX5 2562/4885SMN1; SMN2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.